SDR grafting of a murine antibody using multiple human germline templates to minimize its immunogenicity

Molecular Immunology

Volumn 41, Issue 9, 2004, Pages 863-872

  Gonzales, Noreen R ^a   Padlan, Eduardo A ^b,d   De Pascalis, Roberto ^a   Schuck, Peter ^c   Schlom, Jeffrey ^a   Kashmiri, Syed V S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d University of the Philippines Diliman   (Philippines)

Author keywords

Antibodies; carcinoembryonic antigen; CDRs; CEA; Chinese hamster ovary; CHO; complementarity determining regions; HAMA; human anti murine antibody; SDRs; specificity determining residues; SPR; surface plasmon resonance; variable heavy; variable light; VH; VL

Indexed keywords

ANTIGEN; CARCINOEMBRYONIC ANTIBODY; MONOCLONAL ANTIBODY;

ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DNA TEMPLATE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; IMMUNOGENICITY; ISOTOPE LABELING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; TUMOR CELL LINE;

AMINO ACIDS; ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; COMPLEMENTARITY DETERMINING REGIONS; FLOW CYTOMETRY; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; PEPTIDE FRAGMENTS; PROTEIN ENGINEERING;

CRICETINAE; CRICETULUS GRISEUS; MURINAE;

EID: 3142550714     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2004.03.041     Document Type: Article

References (37)

1. Abrantes M., Magone M.T., Boyd L.F., Schuck P. Adaptation of a surface plasmon resonance biosensor with microfluidics for use with small sample volumes and long contact times. Anal. Chem. 73:2001;2828-2835
2. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254
3. Caldas C., Coelho V.P., Rigden D.J., Neschich G., Moro A.M., Brigido M.M. Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen. Protein Eng. 13:2000;353-360
4. Caldas C., Coelho V., Kalil J., Moro A.M., Maranhao A.Q., Brigido M.M. Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen. Mol. Immunol. 39:2003;941-952
5. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer. 1:2001;118-129
6. Cox J.P., Tomlinson I.M., Winter G. A directory of human germ-line V kappa segments reveals a strong bias in their usage. Eur. J. Immunol. 24:1994;827-836
7. De Pascalis R., Iwahashi M., Tamura M., Padlan E.A., Gonzales N.R., Santos A.D., Giuliano M., Schuck P., Schlom J., Kashmiri S.V. Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. J. Immunol. 169:2002;3076-3084
8. Frankel M.E., Gerhard W. The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus. Mol. Immunol. 16:1979;101-106
9. Gonzales N.R., Schuck P., Schlom J., Kashmiri S.V. Surface plasmon resonance-based competition assay to assess the sera reactivity of variants of humanized antibodies. J. Immunol. Methods. 268:2002;197-210
10. Gonzales N.R., Padlan E.A., De Pascalis R., Schuck P., Schlom J., Kashmiri S.V.S. Minimizing immunogenicity of the SDR-grafted humanized antibody CC49 by genetic manipulation of the framework residues. Mol Immunol. 40:2003;337-349
11. Hakimi J., Chizzonite R., Luke D.R., Familletti P.C., Bailon P., Kondas J.A., Pilson R.S., Lin P., Weber D.V., Spence C., et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J. Immunol. 147:1991;1352-1359
12. Hsiao K.C., Bajorath J., Harris L.J. Humanization of 60.3, an anti-CD18 antibody importance of the L2 loop. Protein Eng. 7:1994;815-822
13. Huston J.S., George A.J. Engineered antibodies take center stage. Hum. Antibodies. 10:2001;127-142
14. Iwahashi M., Milenic D.E., Padlan E.A., Bei R., Schlom J., Kashmiri S.V. CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity. Mol. Immunol. 36:1999;1079-1091
15. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., Dormitzer M., O'Grady J., Koenig S., Tamura J.K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W.C., Young J.F. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 176:1997;1215-1224
16. Jones P.T., Dear P.H., Foote J., Neuberger M.S., Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321:1986;522-525
17. Kabat, E.A., Wu, T., Perry, H.M., Gottesman, K.S., Foeller, C., 1991. Sequence of proteins of immunological interests, fifth ed. NIH Publication No. 91-3242. US Department of Health and Human Services, National Institutes of Health, Bethesda, MD.
18. Kuroki M., Greiner J.W., Simpson J.F., Primus F.J., Guadagni F., Schlom J. Serologic mapping and biochemical characterization of the carcinoembryonic antigen epitopes using fourteen distinct monoclonal antibodies. Int. J. Cancer. 44:1989;208-218
19. Landt O., Grunert H.P., Hahn U. A general method for rapid site-directed mutagenesis using the polymerase chain reaction. Gene. 96:1990;125-128
20. 131I -labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer Clin. Cancer Res. 2:1996;1811-1818
21. Muraro R., Wunderlich D., Thor A., Lundy J., Noguchi P., Cunningham R., Schlom J. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res. 45:1985;5769-5780
22. Ohuchi N., Wunderlich D., Fujita J., Colcher D., Muraro R., Nose M., Schlom J. Differential expression of carcinoembryonic antigen in early gastric adenocarcinomas versus benign gastric lesions defined by monoclonal antibodies reactive with restricted antigen epitopes. Cancer Res. 47:1987;3565-3571
23. Padlan E.A. Anatomy of the antibody molecule. Mol. Immunol. 31:1994;169-217
24. Padlan E.A., Abergel C., Tipper J.P. Identification of specificity-determining residues in antibodies. FASEB J. 9:1995;133-139
25. Primus F.J., Sharkey R.M., Hansen H.J., Goldenberg D.M. Immunoperoxidase detection of carcinoembryonic antigen: an overview. Cancer. 42(Suppl. 3):1978;1540-1545
26. Richards J., Auger J., Peace D., Gale D., Michel J., Koons A., Haverty T., Zivin R., Jolliffe L., Bluestone J.A. Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4. Cancer Res. 59:1999;2096-2101
27. Ritter G., Cohen L.S., Williams C. Jr., Richards E.C., Old L.J., Welt S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res. 61:2001;6851-6859
28. Robbins P.F., Kantor J.A., Salgaller M., Hand P.H., Fernsten P.D., Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 51:1991;3657-3662
29. Rosok M.J., Yelton D.E., Harris L.J., Bajorath J., Hellstrom K.E., Hellstrom I., Cruz G.A., Kristensson K., Lin H., Huse W.D., Glaser S.M. A combinatorial library strategy for the rapid humanization of anticarcinoma BR96. Fab. J. Biol. Chem. 271:1996;22611-22618
30. Ryu C.J., Padlan E.A., Jin B.R., Yoo O.J., Hong H.J. A humanized antibody with specificity for hepatitis B surface antigen. Hum. Antibodies Hybridomas. 7:1996;113-122
31. Schneider W.P., Glaser S.M., Kondas J.A., Hakimi J. The anti-idiotypic response by cynomolgus monkeys to humanized anti-Tac is primarily directed to complementarity-determining regions H1, H2, and L3. J. Immunol. 150:1993;3086-3090
32. Sompuram S.R., Den W., Sharon J. Analysis of antigen binding and idiotypic expression by antibodies with polyglycine-replaced complementarity-determining regions. J. Immunol. 156:1996;1071-1081
33. Stephens S., Emtage S., Vetterlein O., Chaplin L., Bebbington C., Nesbitt A., Sopwith M., Athwal D., Novak C., Bodmer M. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology. 85:1995;668-674
34. Tamura M., Milenic D.E., Iwahashi M., Padlan E., Schlom J., Kashmiri S.V. Structural correlates of an anticarcinoma antibody: identification of specificity-determining residues (SDRs) and development of a minimally immunogenic antibody variant by retention of SDRs only. J. Immunol. 164:2000;1432-1441
35. Tan P., Mitchell D.A., Buss T.N., Holmes M.A., Anasetti C., Foote J. "Superhumanized" antibodies: reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: application to an anti-CD28. J. Immunol. 169:2002;1119-1125
36. Tomlinson I.M., Walter G., Marks J.D., Llewelyn M.B., Winter G. The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J. Mol. Biol. 227:1992;776-798
37. Yu B., Carrasquillo J., Milenic D., Chung Y., Perentesis P., Feuerestein I., Eggensperger D., Qi C.F., Paik C., Reynolds J., Grem J., Curt G., Siler K., Schlom J., Allegra C. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J. Clin. Oncol. 14:1996;1798-1809